Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Evoke Pharma Inc

Get SEC filing alerts via email and in your feed for Evoke Pharma Inc

EVOK

Evoke Pharma Inc

About Evoke Pharma Inc

Evoke Pharma, Inc. develops and commercializes specialized gastrointestinal drugs, primarily focusing on Gimoti, a nasal spray for diabetic gastroparesis. The company partners with Eversana for marketing and distribution, targeting healthcare providers and patients. Its business model emphasizes innovative drug delivery, intellectual property protection, and strategic partnerships to address unmet needs in GI motility disorders within the U.S. healthcare market.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Evoke Pharma Inc

1
1
Evoke Pharma Inc Evoke Pharma Reports 61% Increase in Net Product Sales Despite Ongoing Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Evoke Pharma Inc Evoke Pharma Reports 47% Increase in Net Product Sales Despite Ongoing Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Evoke Pharma Inc Evoke Pharma Reports 77% Increase in Net Product Sales, Faces Ongoing Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Evoke Pharma Inc Evoke Pharma Reports Improved Financials, Increased Cash and Cash Equivalents, and Growing Net Product Sales

Via official filing (AI summary) | over 1 year ago | 0 comments